CD4 and melanoma: Although it is difficult to decipher this alteration and the exact mechanism cannot be determined, we suspect that it represents a stabilization mechanism that CD4+CD25+ T cells use in patients with melanoma; the PD1/PDL1 axis is used by regulatory-T cells to suppress autoreactive-B cells in vivo [31].